Skip to main content
SpringerLink
Log in

Botulinum Toxin Bladder Injection in the Treatment of Neurogenic Detrusor Overactivity and Idiopathic OAB

  • Chapter
  • First Online:
Functional Urologic Surgery in Neurogenic and Oncologic Diseases

Part of the book series: Urodynamics, Neurourology and Pelvic Floor Dysfunctions ((UNPFD))

Abstract

Over the last 50 years, botulinum toxin (BoNT) has been transformed from a cause of life-threatening disease to an effective therapy, mainly for muscle spasticity, blepharospasm, and bladder overactivity. Certainly the use of intradetrusor BoNT for the treatment of DO has revolutionized the care of patients with neurogenic bladder and iOAB, largely improving their quality of life. A recent growing body of evidence suggests that intradetrusor injection of BoNT may have beneficial effects in patients with refractory detrusor overactivity (DO) for conservative and/or medical treatments, and it is a new minimally invasive alternative to bladder augmentation in patients with severe overactive bladder (OAB) symptoms and/or untreatable neurogenic bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sussman D, Patel V, Del Popolo G, et al. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242–9.

    Article  CAS  PubMed  Google Scholar 

  2. Abrams P, Cardozo L, Fall M, Standardisation Sub-committee of the International Continence Society, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;2:167–78.

    Article  Google Scholar 

  3. Del Popolo G. Botulinum toxin A era: little steps towards a better understanding. Eur Urol. 2008;54(1):25–7.

    Article  PubMed  Google Scholar 

  4. Gerridzen RG, Thijssen AM, Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J Urol. 1992;147(2):416–8.

    CAS  PubMed  Google Scholar 

  5. Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65(5):981–90.

    Article  CAS  PubMed  Google Scholar 

  6. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine (Phila Pa). 1976;26 Suppl 24:S129–36.

    Google Scholar 

  7. Fowler C. Systematic review of therapy for neurogenic detrusor overactivity. Can Urol Assoc J. 2011;5(5 Suppl 2):S146–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, Karsenty G, Kessler TM, Schneider M, ’t Hoen L, Blok B. Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol. 2016;69(2):324–33.

    Google Scholar 

  9. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. International Urogynecological Association; International Continence Society. Neurourol Urodyn. 2010;29(1):4–20.

    PubMed  Google Scholar 

  10. Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009;56:810–9.

    Article  PubMed  Google Scholar 

  11. Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. Int Urogynecol J. 2012;23:975–82.

    Article  PubMed  Google Scholar 

  12. Sui GP, Wu C, Roosen A, et al. Modulation of bladder myofibroblast activity: implications for bladder function. Am J Physiol Renal Physiol. 2008;295:F688–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. McCloskey KD. Interstitial cells in the urinary bladder–localization and function. Neurourol Urodyn. 2010;29:82–7.

    Article  PubMed  Google Scholar 

  14. de Groat WC. Highlights in basic autonomic neuroscience: contribution of the urothelium to sensory mechanisms in the urinary bladder. Auton Neurosci. 2013;177:67–71.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ikeda Y, Fry C, Hayashi F, et al. Role of gap junctions in spontaneous activity of the rat bladder. Am J Physiol Renal Physiol. 2007;293:F1018–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. De Wachter S, Smith PP, Tannenbaum C, et al. How should bladder sensation be measured? ICI-RS 2011. Neurourol Urodyn. 2012;31:370–4.

    Article  PubMed  Google Scholar 

  17. Lucas MG, et al. EAU guidelines on urinary incontinence. Partial update March 2015 http://uroweb.org/wp-content/uploads/EAU-Guidelines-Urinary-Incontinence-2015.pdf.

  18. Hannestad YS, et al. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG. 2003;110(3):247–54.

    Article  PubMed  Google Scholar 

  19. Hashim H, et al. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008;102(1):62.

    Article  PubMed  Google Scholar 

  20. Gormley AE, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU guideline. https://www.auanet.org/common/pdf/education/clinical-guidance/Overactive-Bladder.pdf.

  21. Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30.

    Article  CAS  PubMed  Google Scholar 

  22. Siddiqui NY, Wu JM, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol Urodyn. 2010;29 Suppl 1:S18–23. doi:10.1002/nau.20786.

    Article  PubMed  Google Scholar 

  23. Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind. Placebo-Control Trial Eur Urol. 2013;64:249–56.

    CAS  Google Scholar 

  24. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm. 2008;115(4):559–65.

    Article  CAS  PubMed  Google Scholar 

  25. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA Chapter 11. Spore-forming Gram-positive bacilli: bacillus and Clostridium species. In: G.F. Brooks, K.C. Carroll, J.S. Butel, S.A. Morse, T.A. Mietzner (Eds.) Jawetz, Melnick, and Adelberg’s medical microbiology. 26th ed. McGraw-Hill, New York; 2013.

    Google Scholar 

  26. Bing L. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules. 2011;16(1):202–20.

    Google Scholar 

  27. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.

    CAS  PubMed  Google Scholar 

  28. Pistolesi D, Selli C, Rossi B, Stampacchia G. Botulinum toxin type B for type A resistant bladder spasticity. J Urol. 2004;171(2 Pt 1):802–3.

    Article  CAS  PubMed  Google Scholar 

  29. Reitz A, Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol. 2004;171(2 Pt 1):804. discussion 804–5.

    Article  PubMed  Google Scholar 

  30. Mehnert U, Boy S, Schmid M, et al. A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol. 2009;27(3):397–403.

    Article  CAS  PubMed  Google Scholar 

  31. Kuo HC. Comparison of effectiveness of detrusor suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol. 2007;178:1359–63.

    Article  PubMed  Google Scholar 

  32. Hakenberg OW, Linne C, Manseck A, Wirth MP. Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourol Urodyn. 2000;19(5):585–93.

    Article  CAS  PubMed  Google Scholar 

  33. Rule AD, St Sauver JL, Jacobson DJ, et al. Three-dimensional ultrasound bladder characteristics and their association with prostate size and lower urinary tract dysfunction among men in the community. Urology. 2009;74(4):908–13.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005;66:94–8.

    Article  PubMed  Google Scholar 

  35. Mazen A, Torreggiani W, Sheikh M, et al. Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection. Int Urol Nephrol. 2015;47:893–8.

    Article  Google Scholar 

  36. Coelho A, Cruz F, Cruz CD, Avelino A. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012;61(6):1178–84.

    Article  CAS  PubMed  Google Scholar 

  37. Ikeda Y, Zabbarova IV, Birder LA, de Groat WC, McCarthy CJ, Hanna-Mitchell AT, Kanai AJ. Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol. 2012;62(6):1157–64.

    Article  CAS  PubMed  Google Scholar 

  38. Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord. 2012;50(12):904–7.

    Article  CAS  PubMed  Google Scholar 

  39. Krhut J, Samal V, Nemec D, Zvara P. Response to ‘Onabotulinum toxin injection in neurogenic detrusor overactivity: intradetrusor versus suburothelial’. Spinal Cord. 2013;51(9):726.

    Article  CAS  PubMed  Google Scholar 

  40. Shenot PJ, Mark JR. Intradetrusor onabotulinumtoxinA injection: how i do it. Can J Urol. 2013;20(1):6649–55.

    PubMed  Google Scholar 

  41. Nitti A, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized. Placebo Control Trial J Urol. 2013;189:2186–93.

    CAS  Google Scholar 

  42. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41(4):335–40.

    Article  CAS  PubMed  Google Scholar 

  43. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50.

    Article  CAS  PubMed  Google Scholar 

  44. Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60(4):784–95.

    Article  CAS  PubMed  Google Scholar 

  45. Mehta S, Hill D, McIntyre A, et al. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil. 2013;94(8):1473–81.

    Article  PubMed  Google Scholar 

  46. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.

    Article  CAS  PubMed  Google Scholar 

  47. Soljanik I. Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review. Drugs. 2013;73(10):1055–66. doi:10.1007/s40265-013-0068-5.

    Article  CAS  PubMed  Google Scholar 

  48. Schurch B, de Sèze M, Denys P, et al. Botox Detrusor Hyperreflexia Study Team Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200.

    Article  CAS  PubMed  Google Scholar 

  49. Kennelly M, Dmochowski R, Schulte-Baukloh H, Ethans K, Del Popolo G. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourol Urodyn. 2015. doi: 10.1002/nau.22934.

    Google Scholar 

  50. Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 2005;96(6):848–52.

    Article  CAS  PubMed  Google Scholar 

  51. Del Popolo G. Botulinum-A toxin in the treatment of detrusor hyperreflexia. Abstract n 93. ICS annual meeting, Seoul; 2001.

    Google Scholar 

  52. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40(11):599–600.

    Article  CAS  PubMed  Google Scholar 

  53. Del Popolo G, Filocamo MT, Li Marzi V, et al. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol. 2008;53(5):1013–9.

    Article  PubMed  Google Scholar 

  54. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47:653–9.

    Article  CAS  PubMed  Google Scholar 

  55. Gregoriadis G, Ryman BE. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem J. 1971;124(5):58.

    Article  Google Scholar 

  56. Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm. 2005;300(1–2):125–30.

    Article  CAS  PubMed  Google Scholar 

  57. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005;2(4):369–81.

    Article  CAS  PubMed  Google Scholar 

  58. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995;13(12):527–37.

    Article  CAS  PubMed  Google Scholar 

  59. Gregoriadis G, Allison AC. Entrapment of proteins in liposomes prevents allergic reactions in pre immunised mice. FEBS Lett. 1974;45(1):71–4.

    Article  CAS  PubMed  Google Scholar 

  60. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol. 2005;50(2):167–82.

    Article  PubMed  Google Scholar 

  61. Kaufman J, Tyagi P, Chancellor MB. Intravesical liposomal (Lp08) instillation protects bladder urothelium from chemical irritation. J Urol. 2009;181, article 539.

    Google Scholar 

  62. Tyagi P, Chancellor MB, Li Z, et al. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol. 2004;171(1):483–9.

    Article  CAS  PubMed  Google Scholar 

  63. Fraser MO, Chuang Y-C, Tyagi P, et al. Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat. Urology. 2003;61(3):656–63.

    Article  PubMed  Google Scholar 

  64. Tyagi P, Chancellor M, Yoshimura N, Huang L. Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU Int. 2008;101(5):627–32.

    Article  CAS  PubMed  Google Scholar 

  65. Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis—a practical approach. Urology. 1997;49(5):105–7.

    Article  CAS  PubMed  Google Scholar 

  66. Sun Y, Chai TC. Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis. BJU Int. 2002;90(4):381–5.

    Article  CAS  PubMed  Google Scholar 

  67. Bade JJ. A placebo-controlled study of intravesical pentosan- polysulphate for the treatment of interstitial cystitis. Br J Urol. 1997;79(2):168–71.

    Article  CAS  PubMed  Google Scholar 

  68. Tyagi P, Hsieh VC, Yoshimura N, Kaufman J, Chancellor MB. Instillation of liposomes vs dimethyl sulphoxide or pentosan polysulphate for reducing bladder hyperactivity. BJU Int. 2009;104(11):1689–92.

    Article  CAS  PubMed  Google Scholar 

  69. Chuang Y-C, Lee W-C, Lee W-C, Chiang P-H. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009;182(4):1393–400.

    Article  CAS  PubMed  Google Scholar 

  70. Chancellor MB, De Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol. 1999;162(1):3–11.

    Article  CAS  PubMed  Google Scholar 

  71. Byrne DS, Das A, Sedor J, et al. Effect of intravesical capsaicin and vehicle on bladder integrity in control and spinal cord injured rats. J Urol. 1998;159(3):1074–8.

    Article  CAS  PubMed  Google Scholar 

  72. Mandal M, Lee K-D. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta. 2002;1563(1–2):7–17.

    Article  CAS  PubMed  Google Scholar 

  73. Chuang Y-C, Tyagi P, Huang C-C, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin a delivery using liposomes. J Urol. 2009;182(2):786–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Careggi University Hospital, Florence, Italy

    Vincenzo Li Marzi, Jacopo Frizzi & Matteo Bonifazi

  2. Neurourology Unit, Careggi University Hospital, Florence, Italy

    Giulio Del Popolo

Authors
  1. Vincenzo Li Marzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacopo Frizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matteo Bonifazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giulio Del Popolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Li Marzi .

Editor information

Editors and Affiliations

  1. Dept Medico-Surgical Sci&Biotechnologies, Sapienza University of Rome, Rome, Italy

    Antonio Carbone

  2. Dept Medico-Surgical Sci&Biotechnologies, Sapienza University of Rome, Rome, Italy

    Giovanni Palleschi

  3. Dept Medico-Surgical Sci&Biotechnologies, Sapienza University of Rome, Rome, Italy

    Antonio Luigi Pastore

  4. Urologic Surgery, Max Fourestier Hospital, Nanterre, France

    Aurel Messas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Li Marzi, V., Frizzi, J., Bonifazi, M., Del Popolo, G. (2016). Botulinum Toxin Bladder Injection in the Treatment of Neurogenic Detrusor Overactivity and Idiopathic OAB. In: Carbone, A., Palleschi, G., Pastore, A., Messas, A. (eds) Functional Urologic Surgery in Neurogenic and Oncologic Diseases. Urodynamics, Neurourology and Pelvic Floor Dysfunctions. Springer, Cham. https://doi.org/10.1007/978-3-319-29191-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29191-8_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-29189-5

  • Online ISBN: 978-3-319-29191-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation